Roche, Zealand Pharma Obesity Drug Meets Clinical Trial’s Weight Loss Goals, But Can It Compete? - MedCity News
Research on obesity drugs is expanding beyond GLP-1, with Zealand Pharma and Roche's petrelintide showing promising tolerability comparable to a placebo, although the weight loss results have raised concerns among analysts regarding its competitiveness. Preliminary Phase 2 results indicate a 10.7% average weight reduction from baseline at week 42, but analysts suggest that the drug's potential may be limited by a ceiling effect on weight loss despite its favorable side effect profile.
The most valuable insight for you is that Zealand Pharma and Roche are exploring the potential of petrelintide as a maintenance treatment due to its tolerability profile, despite its relatively modest weight loss efficacy compared to other drugs like Eli Lilly’s eloralintide. This positions petrelintide as a potentially valuable component in combination therapies, especially with Roche's CT-388, which targets GLP-1 and GIP receptors. This strategic shift suggests an opportunity to monitor developments in combination treatments involving amylin analogs for obesity and possibly consider investment or partnership opportunities in this evolving space.